Proposed Dual-Listing on Nasdaq

b'GAITHERSBURG, Md., May 14, 2021 /PRNewswire/ --MaxCyte, Inc. (LSE: MXCT, MXCL, MXCN) ("MaxCyte" or the "Company"), a leading provider of platform technologies for cell engineering, today announces that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC") relating to a proposed dual-listing and public offering of shares of common stock on the Nasdaq Stock Market (the "Offering").\nThe number of securities to be offered and the price for the proposed Offering have not yet been determined.